Drugmakers — major beneficiaries of NIH-backed university research — have been largely silence on the Trump administration's cuts to agency research payments.
Raw Story on MSN1h
Russell Vought's kid got life-saving drug — that his policies are now attacking: reportThe daughter of a key architect of Project 2025 benefitted from a life-changing drug — which was created with the help of the ...
The drastic reduction in indirect costs is not a path to innovation or cost savings — it’s a threat to U.S.’s position as ...
THE FALLOUT OF NIH’S GRANT CAP — The National Institutes of Health’s announcement that it would slash grants to research ...
A new journal purports to improve the publishing process through open access and public peer review, but it was co-founded by ...
But that's not so. Indirect costs include lab space, data storage, regulatory compliance and administrative support. The ...
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
The journal’s editorial board includes multiple scientists, such as Trump health nominees Jay Bhattacharya and Marty Makary, ...
A sweeping shift in federal policy—capped, at least temporarily, by a federal judge’s decision to halt the NIH’s proposed 15% ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
The phase 2 CAFETERIA study included participants aged 4 to 14 years who were able to tolerate at least 143mg of peanut protein.
Our recent study, published in the Journal of Health Politics, Policy and Law, tracks how the Trump administration applied public pressure on the FDA during the 2020 election season, sparking a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback